Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.

The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Boris Itkin, Agustin Garcia, Samanta Straminsky, Eduardo Daniel Adelchanow, Matias Pereyra, Gabriela Acosta Haab, Ariel Bardach
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ab8ebf92343e4ebdb6a4668c08a9319c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ab8ebf92343e4ebdb6a4668c08a9319c
record_format	dspace
spelling	oai:doaj.org-article:ab8ebf92343e4ebdb6a4668c08a9319c2021-12-02T20:13:54ZPrevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.1932-620310.1371/journal.pone.0257976https://doaj.org/article/ab8ebf92343e4ebdb6a4668c08a9319c2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0257976https://doaj.org/toc/1932-6203The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.Boris ItkinAgustin GarciaSamanta StraminskyEduardo Daniel AdelchanowMatias PereyraGabriela Acosta HaabAriel BardachPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0257976 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Boris Itkin Agustin Garcia Samanta Straminsky Eduardo Daniel Adelchanow Matias Pereyra Gabriela Acosta Haab Ariel Bardach Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
description	The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.
format	article
author	Boris Itkin Agustin Garcia Samanta Straminsky Eduardo Daniel Adelchanow Matias Pereyra Gabriela Acosta Haab Ariel Bardach
author_facet	Boris Itkin Agustin Garcia Samanta Straminsky Eduardo Daniel Adelchanow Matias Pereyra Gabriela Acosta Haab Ariel Bardach
author_sort	Boris Itkin
title	Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
title_short	Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
title_full	Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
title_fullStr	Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
title_full_unstemmed	Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
title_sort	prevalence of her2 overexpression and amplification in cervical cancer: a systematic review and meta-analysis.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/ab8ebf92343e4ebdb6a4668c08a9319c
work_keys_str_mv	AT borisitkin prevalenceofher2overexpressionandamplificationincervicalcancerasystematicreviewandmetaanalysis AT agustingarcia prevalenceofher2overexpressionandamplificationincervicalcancerasystematicreviewandmetaanalysis AT samantastraminsky prevalenceofher2overexpressionandamplificationincervicalcancerasystematicreviewandmetaanalysis AT eduardodanieladelchanow prevalenceofher2overexpressionandamplificationincervicalcancerasystematicreviewandmetaanalysis AT matiaspereyra prevalenceofher2overexpressionandamplificationincervicalcancerasystematicreviewandmetaanalysis AT gabrielaacostahaab prevalenceofher2overexpressionandamplificationincervicalcancerasystematicreviewandmetaanalysis AT arielbardach prevalenceofher2overexpressionandamplificationincervicalcancerasystematicreviewandmetaanalysis
_version_	1718374728215822336

Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.

Ejemplares similares